IBM researchers have developed a new polymer-like material to treat fungal infections.
Personal genetics company 23andMe will only sell ancestry reports and raw data as controversy with regulators continues.
A new brain-imaging technology may reveal the true risk of repetitive head injury in contact sports.
Delivering healthy bacteria in a pill could help patients harboring out-of-balance microbial communities.
The search giant says patents are rubbish. Yet it’s accumulating more of them than ever.
A Boston startup wants to create precise genome-editing treatments that can address more types of disease than previous gene therapy methods.
Physicists have developed a technique that can tell which parts of the brain rely on analog signals and which rely on digital signals.
The U.S. government is concerned that some of 23andMe’s health assessments could mislead customers.
Researchers uncover new ties between genetics and skin cancer by mining patients’ medical records.
How does the ability to instantaneously reallocate physical resources change the way companies source materials, manage operations, and go to market?